Ligand-targeted theranostic nanomedicines against cancer.
暂无分享,去创建一个
Kimberly S Butler | Wadih Arap | Renata Pasqualini | C Jeffrey Brinker | Juri G Gelovani | Andrew R M Bradbury | Kimberly S. Butler | R. Sidman | C. Brinker | W. Arap | A. Bradbury | R. Pasqualini | A. Dobroff | J. Gelovani | S. Marchiò | K. Butler | Sara D'Angelo | Virginia J. Yao | Virginia J Yao | Christophe Theron | Tracey L Smith | Serena Marchiò | Richard L Sidman | Andrey S Dobroff | C. Théron | Tracey L. Smith | S. D’Angelo
[1] M. Cilli,et al. The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. , 2015, Cancer research.
[2] M. Cilli,et al. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[3] Avelino Corma,et al. Monodispersed mesoporous silica nanoparticles with very large pores for enhanced adsorption and release of DNA. , 2009, The journal of physical chemistry. B.
[4] Wadih Arap,et al. Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.
[5] M. Ozawa,et al. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma , 2005, Cancer.
[6] Jan Berka,et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.
[7] V. Torchilin,et al. Comparative studies on covalent and noncovalent immobilization of protein molecules on the surface of liposomes. , 1978, Biochemical and biophysical research communications.
[8] Kim-Anh Do,et al. A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys , 2011, Science Translational Medicine.
[9] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] Kwangmeyung Kim,et al. Tumor‐Targeting Multifunctional Nanoparticles for siRNA Delivery: Recent Advances in Cancer Therapy , 2014, Advanced healthcare materials.
[11] M. Karplus,et al. Three key residues form a critical contact network in a protein folding transition state , 2001, Nature.
[12] S. Simon,et al. Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.
[13] Seong Huh,et al. Organic Functionalization and Morphology Control of Mesoporous Silicas via a Co-Condensation Synthesis Method , 2003 .
[14] C. Benz,et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine , 2009, Cancer Chemotherapy and Pharmacology.
[15] V. Torchilin,et al. Current trends in the use of liposomes for tumor targeting. , 2013, Nanomedicine.
[16] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[17] Eric C. Carnes,et al. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. , 2013, Accounts of chemical research.
[18] John F. McDonald,et al. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. , 2008, Journal of the American Chemical Society.
[19] Rui Zhang,et al. Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer. , 2015, International journal of pharmaceutics.
[20] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[21] Xin Du,et al. Tunable stellate mesoporous silica nanoparticles for intracellular drug delivery. , 2015, Journal of materials chemistry. B.
[22] Zongxi Li,et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. , 2010, Small.
[23] Craig A. Poland,et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. , 2008, Nature nanotechnology.
[24] T. Kodama,et al. Structure-based design of a streptavidin mutant specific for an artificial biotin analogue. , 2015, Journal of biochemistry.
[25] R. Sidman,et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment , 2012, Proceedings of the National Academy of Sciences.
[26] So Jin Lee,et al. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[27] Yi-Xiang J. Wang. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. , 2011, Quantitative imaging in medicine and surgery.
[28] F. Martin,et al. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. , 1981, Biochemistry.
[29] G. Adams,et al. Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity1 , 2001, Journal of Immunology.
[30] Julien Gravier,et al. Fluorescent Nanoprobes Dedicated to in Vivo Imaging: From Preclinical Validations to Clinical Translation , 2012, Molecules.
[31] Lu Liu,et al. The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human prostate cancer cells. , 2012, Oncology letters.
[32] S. Savarala,et al. Formation and colloidal stability of DMPC supported lipid bilayers on SiO2 nanobeads. , 2010, Langmuir : the ACS journal of surfaces and colloids.
[33] Anthony D. Keefe,et al. Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.
[34] J. Chen,et al. Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer , 2011, Frontiers of medicine.
[35] Ronnie H. Fang,et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.
[36] Ceirin M. Connolly-Ingram,et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[37] K. Fujimori,et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.
[38] X. Chen,et al. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. , 2014, Biomaterials.
[39] Matthew R Cooperberg,et al. Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells , 2004, Cancer Research.
[40] C. Benz,et al. Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.
[41] T. Park,et al. Clustered magnetite nanocrystals cross-linked with PEI for efficient siRNA delivery. , 2011, Biomacromolecules.
[42] C. Leuschner,et al. Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases , 2007, Molecular and Cellular Endocrinology.
[43] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[44] H. Mukundan,et al. Using Phage and Yeast Display to Select Hundreds of Monoclonal Antibodies: Application to Antigen 85, a Tuberculosis Biomarker , 2012, PloS one.
[45] Da Xing,et al. Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. , 2015, Biomaterials.
[46] Qinfu Zhao,et al. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance. , 2015, ACS applied materials & interfaces.
[47] R. Siegel,et al. Yeast display of antibody fragments: a discovery and characterization platform. , 2004, Journal of immunological methods.
[48] Junqing Hu,et al. One-pot morphology-controlled synthesis of various shaped mesoporous silica nanoparticles , 2013, Journal of Materials Science.
[49] Hongchen Gu,et al. The packaging of siRNA within the mesoporous structure of silica nanoparticles. , 2011, Biomaterials.
[50] Il-Kwon Oh,et al. Graphene oxide-polyethylenimine nanoconstruct as a gene delivery vector and bioimaging tool. , 2011, Bioconjugate chemistry.
[51] E. Yonemochi,et al. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes , 2015, Journal of liposome research.
[52] Hairong Zheng,et al. Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. , 2014, Biotechnology advances.
[53] Wadih Arap,et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. , 2002, Cancer research.
[54] W. Arap,et al. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. , 2005, Chemistry & biology.
[55] S. Bates,et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. , 2005, Cancer research.
[56] U. Nielsen,et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. , 2012, Toxicology and applied pharmacology.
[57] Peter Walter,et al. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase , 1993, Cell.
[58] T. Chatterjee,et al. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis , 2005, Journal of drug targeting.
[59] Selection and Application of DNA Aptamer Against Oncogene Amplified in Breast Cancer 1 , 2015, Journal of Molecular Evolution.
[60] Evan Phillips,et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. , 2012, Integrative biology : quantitative biosciences from nano to macro.
[61] G. Adams,et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.
[62] S. Furmaniak,et al. The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System , 2015 .
[63] Tudor I. Oprea,et al. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis , 2015, Proceedings of the National Academy of Sciences.
[64] Andreas Plückthun,et al. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display , 2000, Nature Biotechnology.
[65] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[66] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[67] P. Schlesinger,et al. A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. , 2015, Biotechnology advances.
[68] V. Petrenko,et al. Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins , 2015, Front. Microbiol..
[69] M. Ozawa,et al. The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1. , 2007, Cancer research.
[70] D. Krag,et al. Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies , 2013, Cancer Immunology, Immunotherapy.
[71] W. Arap,et al. αvβ5 Integrin-Dependent Programmed Cell Death Triggered by a Peptide Mimic of Annexin V , 2003 .
[72] J. F. Stoddart,et al. Controlled-access hollow mechanized silica nanocontainers. , 2009, Journal of the American Chemical Society.
[73] D. Maloney,et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .
[74] R. Marzari,et al. In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. , 2001, Journal of biotechnology.
[75] K. Gelmon,et al. Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[76] K. Greish,et al. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect , 2014, International journal of nanomedicine.
[77] W. Arap,et al. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage–mediated, vascular-targeted suicide gene transfer , 2009, Molecular Cancer Therapeutics.
[78] R. Sidman,et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors , 2015, Proceedings of the National Academy of Sciences.
[79] J. Sambrook,et al. A transmembrane protein with a cdc2+ CDC28 -related kinase activity is required for signaling from the ER to the nucleus , 1993, Cell.
[80] R. Sidman,et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.
[81] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] T. Skorski,et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. , 2011, Blood.
[83] P. Pavlík,et al. A comprehensive analysis of filamentous phage display vectors for cytoplasmic proteins: an analysis with different fluorescent proteins , 2009, Nucleic acids research.
[84] Sanne Kuijper,et al. Regulation of angiogenesis by Eph-ephrin interactions. , 2007, Trends in cardiovascular medicine.
[85] Kim-Anh Do,et al. Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.
[86] Indrajit Roy,et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.
[87] M. Finn,et al. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001 .
[88] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[89] S. Libutti,et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. , 2008, Cancer research.
[90] D. F. Barber,et al. Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[91] R. Millikan,et al. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study , 2015, Cancer.
[92] G. Adams,et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.
[93] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[94] S. Libutti,et al. Tumor vasculature‐targeted delivery of tumor necrosis factor‐α * , 2009, Cancer.
[95] London Wc,et al. De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity , 1996 .
[96] A. K. Swain,et al. Polymer Stabilized Fe3O4-Graphene as an Amphiphilic Drug Carrier for Thermo-Chemotherapy of Cancer. , 2015, ACS applied materials & interfaces.
[97] C. Leuschner,et al. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo , 2007, Molecular and Cellular Endocrinology.
[98] Jinho Park,et al. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.
[99] Fortunato Ferrara,et al. The antibody mining toolbox , 2013, mAbs.
[100] P. Troncoso,et al. Combinatorial Screenings in Patients , 2004, Cancer Research.
[101] A. S. Lee,et al. Biochemical characterization of the 94- and 78-kilodalton glucose-regulated proteins in hamster fibroblasts. , 1984, The Journal of biological chemistry.
[102] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[103] Robert Langer,et al. Impact of nanotechnology on drug delivery. , 2009, ACS nano.
[104] U. Nielsen,et al. Selection of tumor-specific internalizing human antibodies from phage libraries. , 2000, Journal of molecular biology.
[105] Janice M Reichert,et al. Antibodies to watch in 2015 , 2015, mAbs.
[106] Green Nm,et al. Avidin and streptavidin. , 1990 .
[107] Tudor I. Oprea,et al. Chemography: the Art of Navigating in Chemical Space , 2000 .
[108] T. Iwamoto. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. , 2013, Biological & pharmaceutical bulletin.
[109] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[110] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] R. Schiff,et al. Cancer Cells Resistant to Therapy Promote Cell Surface Relocalization of GRP78 Which Complexes with PI3K and Enhances PI(3,4,5)P3 Production , 2013, PloS one.
[112] Srikanth K. Iyer,et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.
[113] W. Arap,et al. GRP78 signaling hub a receptor for targeted tumor therapy. , 2010, Advances in genetics.
[114] Enzo Di Fabrizio,et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.
[115] M. Ozawa,et al. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. , 2005, The American journal of pathology.
[116] Elodie Boisselier,et al. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. , 2009, Chemical Society reviews.
[117] M. Pellecchia,et al. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. , 2012, Journal of medicinal chemistry.
[118] Cheng-Chung Chou,et al. Single-walled carbon nanotubes can induce pulmonary injury in mouse model. , 2008, Nano letters.
[119] Shi Ke,et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. , 2007, Bioconjugate chemistry.
[120] Roberto Scalamogna,et al. Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors , 2011, Clinical Cancer Research.
[121] R. Sidman,et al. Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells , 2012, Nature Communications.
[122] Yu‐quan Wei,et al. Enhancement of cisplatin sensitivity in lewis lung carcinoma by liposome-mediated delivery of a survivin mutant , 2010, Journal of experimental & clinical cancer research : CR.
[123] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[124] H. Gu,et al. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy , 2015, International journal of nanomedicine.
[125] K. Ng,et al. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. , 2013, Chemistry.
[126] Iseult Lynch,et al. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[127] Dong Chen,et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. , 2010, ACS nano.
[128] Thomas Lars Andresen,et al. Engineering liposomes and nanoparticles for biological targeting. , 2011, Advances in biochemical engineering/biotechnology.
[129] Emmanuel Dias-Neto,et al. Next-Generation Phage Display: Integrating and Comparing Available Molecular Tools to Enable Cost-Effective High-Throughput Analysis , 2009, PloS one.
[130] Weihong Tan,et al. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. , 2004, Chemical communications.
[131] B. Aggarwal,et al. A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications1 , 2007, The Journal of Immunology.
[132] C. Lilley,et al. A Hybrid Vector for Ligand-Directed Tumor Targeting and Molecular Imaging , 2006, Cell.
[133] S. Pizzo,et al. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. , 2006, Cancer research.
[134] E. Ruoslahti,et al. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. , 1993, The Journal of biological chemistry.
[135] V. S. Lin,et al. Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization. , 2012, Molecular pharmaceutics.
[136] Jason L. Townson,et al. Delivery of Ricin Toxin A‐Chain by Peptide‐Targeted Mesoporous Silica Nanoparticle‐Supported Lipid Bilayers , 2012, Advanced healthcare materials.
[137] Tian Xia,et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. , 2013, ACS nano.
[138] Nelson Durán,et al. Nanotoxicity of graphene and graphene oxide. , 2014, Chemical research in toxicology.
[139] Zhuang Liu,et al. Graphene based gene transfection. , 2011, Nanoscale.
[140] K. Sikora,et al. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. , 1990, British Journal of Cancer.
[141] Michael M. Schmidt,et al. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability , 2008, Cancer Immunology, Immunotherapy.
[142] S. Bhattarai,et al. Enhanced Gene and siRNA Delivery by Polycation-Modified Mesoporous Silica Nanoparticles Loaded with Chloroquine , 2010, Pharmaceutical Research.
[143] Xin Du,et al. Label-free dendrimer-like silica nanohybrids for traceable and controlled gene delivery. , 2014, Biomaterials.
[144] C. Logothetis,et al. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. , 2003, The Hastings Center report.
[145] W. Arap,et al. Targeting neuropilin-1 in human leukemia and lymphoma. , 2011, Blood.
[146] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[147] W. Hong,et al. Phenotypic diversity of the lung vasculature in experimental models of metastases. , 2005, Chest.
[148] Mithat Gönen,et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe , 2014, Science Translational Medicine.
[149] H. Stunnenberg,et al. Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[150] Victor S-Y Lin,et al. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. , 2004, Journal of the American Chemical Society.
[151] H R Hoogenboom,et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.
[152] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[153] Baldomero Oliva,et al. Multivalent antibodies: when design surpasses evolution. , 2010, Trends in biotechnology.
[154] I. Pastan,et al. Advances in anticancer immunotoxin therapy. , 2015, The oncologist.
[155] Yu Zhou,et al. Building and characterizing antibody-targeted lipidic nanotherapeutics. , 2012, Methods in enzymology.
[156] David A Winkler,et al. Tripeptide motifs in biology: targets for peptidomimetic design. , 2011, Journal of medicinal chemistry.
[157] D. Cramb,et al. Designing a better theranostic nanocarrier for cancer applications. , 2014, Nanomedicine.
[158] S. Chiou,et al. Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. , 2013, ACS nano.
[159] J. Wower,et al. Therapeutic RNA aptamers in clinical trials. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[160] Zongxi Li,et al. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.
[161] M. Ozawa,et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. , 2009, Cancer research.
[162] Pedro V. Baptista,et al. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine , 2014, Front. Chem..
[163] Darrell J Irvine,et al. Drug delivery: One nanoparticle, one kill. , 2011, Nature materials.
[164] D. Parry,et al. Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. , 2008, Journal of structural biology.
[165] Wadih Arap,et al. From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway , 2010, Proceedings of the National Academy of Sciences.
[166] R. Sidman,et al. Bone marrow-derived CD13+ cells sustain tumor progression , 2014, Oncoimmunology.
[167] Min Woo Park,et al. An RNA aptamer that binds to the β-catenin interaction domain of TCF-1 protein , 2005 .
[168] Lyndsay Harris,et al. Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.
[169] Erkki Ruoslahti,et al. Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.
[170] Valentina Cauda,et al. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. , 2010, Nano letters.
[171] Sanjiv S Gambhir,et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. , 2008, Nature nanotechnology.
[172] Vittorio Cristini,et al. Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. , 2013, ACS nano.
[173] F. Bidard,et al. Trends in cancer-targeted antibody–drug conjugates , 2014, Targeted Oncology.
[174] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[175] J. Pedraz,et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research , 2012, Clinical and Translational Oncology.
[176] L. Ellis,et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients , 2004, Oncogene.
[177] Lev Dykman,et al. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.
[178] S. Futaki,et al. Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment , 2009, The AAPS Journal.
[179] Emmanuel Dias-Neto,et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients , 2011, Proceedings of the National Academy of Sciences.
[180] S. Ramalingam,et al. Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies , 2009, Clinical Cancer Research.
[181] Bengt Fadeel,et al. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. , 2011, Biochimica et biophysica acta.
[182] H. Zou,et al. In vivo detection of magnetic labeled oxidized multi-walled carbon nanotubes by magnetic resonance imaging , 2014, Nanotechnology.
[183] M. Ozawa,et al. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. , 2006, Cancer research.
[184] A. Bradbury,et al. Antibodies from phage antibody libraries. , 2004, Journal of immunological methods.
[185] D. Neri,et al. Immunocytokines: a review of molecules in clinical development for cancer therapy , 2013, Clinical pharmacology : advances and applications.
[186] R. Amado,et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice , 2007, Nature Biotechnology.
[187] W. Wriggers,et al. Cross-linking constraints on F-actin structure. , 2000, Journal of molecular biology.
[188] W. Arap,et al. A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6 , 2012, EMBO molecular medicine.
[189] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[190] Chung-Yuan Mou,et al. Multifunctional Mesoporous Silica Nanoparticles for Intracellular Labeling and Animal Magnetic Resonance Imaging Studies , 2008, Chembiochem : a European journal of chemical biology.
[191] Ira Mellman,et al. Antibody Therapeutics in Cancer , 2013, Science.
[192] Vladimir P Torchilin,et al. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes , 2007, Journal of drug targeting.
[193] V. Torchilin,et al. Preservation of antimyosin antibody activity after covalent coupling to liposomes. , 1979, Biochemical and biophysical research communications.
[194] Yaping Li,et al. Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. , 2009, Small.
[195] Saji George,et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. , 2009, ACS nano.
[196] Daniele Sblattero,et al. Exploiting recombination in single bacteria to make large phage antibody libraries , 2000, Nature Biotechnology.
[197] Shenda Gu,et al. Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. , 2015, Biomaterials.
[198] F. Chen,et al. Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections , 2014, Theranostics.
[199] T. Kodama,et al. Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin , 2013, Protein science : a publication of the Protein Society.
[200] S W Burchiel,et al. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. , 2009, Nature nanotechnology.
[201] P. T. Jones,et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.
[202] Wadih Arap,et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[203] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[204] S. Libutti,et al. Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature , 2009, PloS one.
[205] Hyesung Jeon,et al. Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. , 2011, ACS nano.
[206] W. Arap,et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. , 2004, Cancer cell.
[207] Jason L. Townson,et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. , 2012, ACS nano.
[208] J. Pelletier,et al. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. , 1998, Nucleic acids research.
[209] Yuan Zhang,et al. Progress in Aptamer-Mediated Drug Delivery Vehicles for Cancer Targeting and Its Implications in Addressing Chemotherapeutic Challenges , 2014, Theranostics.
[210] Morteza Mahmoudi,et al. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. , 2012, Chemical reviews.
[211] Samuel A. Mihelic,et al. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer , 2015, Advanced functional materials.
[212] S. Reddy,et al. Deep sequencing in library selection projects: what insight does it bring? , 2015, Current opinion in structural biology.
[213] R. Sidman,et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3 , 2015, Proceedings of the National Academy of Sciences.
[214] H. Fasold,et al. [32] Cross-linking techniques , 1989 .
[215] C. Jeffrey Brinker,et al. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. , 2009, Journal of the American Chemical Society.
[216] Xiao-ling Fang,et al. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[217] M. Ozawa,et al. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment , 2009, Proceedings of the National Academy of Sciences.
[218] K. Keinänen,et al. Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. , 1993, Protein engineering.
[219] Meiying Wang,et al. Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice , 2015, ACS nano.
[220] R Pasqualini,et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.
[221] John C Bischof,et al. Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. , 2009, Nanomedicine.
[222] Marcus Textor,et al. Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. , 2011, Nano letters.
[223] H. Kolmar,et al. Therapeutic antibody engineering by high efficiency cell screening , 2014, FEBS letters.
[224] Kim-Anh Do,et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. , 2006, Cancer research.
[225] R. Sperling,et al. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[226] Y. Zu,et al. Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.
[227] P. Roche,et al. A receptor binding site identified in the region 81–95 of the β-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG) , 1993, Molecular and Cellular Endocrinology.
[228] Sachdev S Sidhu,et al. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. , 2008, Journal of molecular biology.
[229] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[230] Amy S. Lee. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. , 2005, Methods.
[231] P. T. Jones,et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.
[232] Wadih Arap,et al. From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway , 2010, Proceedings of the National Academy of Sciences.
[233] K. Wittrup,et al. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. , 2004, Nucleic acids research.
[234] R Pasqualini,et al. NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.
[235] Xin Du,et al. Dendritic silica particles with center-radial pore channels: promising platforms for catalysis and biomedical applications. , 2015, Small.
[236] R. Sidman,et al. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease , 2015, Science Translational Medicine.
[237] M. Cilli,et al. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. , 2015, Biomaterials.
[238] Michael Hust,et al. Expression of Recombinant Antibodies , 2013, Front. Immunol..
[239] J. Gershoni,et al. Biotin binding to avidin. Oligosaccharide side chain not required for ligand association. , 1987, The Biochemical journal.
[240] Wadih Arap,et al. Probing the structural and molecular diversity of tumor vasculature. , 2002, Trends in molecular medicine.
[241] M. Singh,et al. Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[242] H. Harashima,et al. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[243] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[244] Xinglu Huang,et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. , 2011, Biomaterials.
[245] A. Plückthun,et al. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. , 1998, Biochemistry.
[246] T. Bein,et al. Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. , 2013, Nano letters.
[247] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[248] Wadih Arap,et al. Reversal of obesity by targeted ablation of adipose tissue , 2004, Nature Medicine.
[249] R. Sidman,et al. Discovery of DNA repair inhibitors by combinatorial library profiling. , 2011, Cancer research.
[250] N. Pavlakis,et al. Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines , 2014, Cancer Immunology Research.
[251] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[252] Andreas Plückthun,et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.
[253] T. Boulikas,et al. Lipoplatin Formulation Review Article , 2011, Journal of drug delivery.
[254] Jianliang Shen,et al. Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of siRNA Cancer Therapeutics , 2014, Theranostics.
[255] Hiroyuki Nishimori,et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. , 2011, The Journal of clinical investigation.
[256] G. Ceresoli,et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[257] Diane D. Liu,et al. Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer , 2015, The Journal of Biological Chemistry.
[258] L. Wyns,et al. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. , 1999, Structure.
[259] Tianfeng Chen,et al. Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways. , 2015, Biomaterials.
[260] J. Zink,et al. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[261] Kim-Anh Do,et al. Fingerprinting the circulating repertoire of antibodies from cancer patients , 2003, Nature Biotechnology.
[262] Duxin Sun,et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. , 2013, Biomaterials.
[263] Shiroh Futaki,et al. Octaarginine-modified multifunctional envelope-type nano device for siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[264] Markus Miettinen,et al. Coiled-Coils in Phage Display Screening: Insight into Exceptional Selectivity Provided by Molecular Dynamics , 2015, J. Chem. Inf. Model..
[265] Zuoming Zhang,et al. Adsorption and protection of plasmid DNA on mesoporous silica nanoparticles modified with various amounts of organosilane. , 2012, Journal of colloid and interface science.
[266] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[267] Tian Xia,et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. , 2011, ACS nano.
[268] P. Sapra,et al. The next generation of antibody drug conjugates. , 2014, Seminars in oncology.
[269] Christy L Haynes,et al. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. , 2010, Journal of the American Chemical Society.
[270] Erkki Ruoslahti,et al. A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[271] Ya‐Ping Sun,et al. Carbon nanoparticles trapped in vivo-similar to carbon nanotubes in time-dependent biodistribution. , 2014, ACS applied materials & interfaces.
[272] Amy S. Lee. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential , 2014, Nature Reviews Cancer.
[273] Dong Chen,et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.
[274] Mark B. Carter,et al. The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers , 2011, Nature materials.
[275] R. Prassl,et al. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[276] J. A. Grant,et al. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..
[277] T. Clackson,et al. Making antibody fragments using phage display libraries , 1991, Nature.
[278] Huan Meng,et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. , 2013, ACS nano.
[279] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[280] K. Okuyama,et al. Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters , 2009 .
[281] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[282] M. Kolonin,et al. Targeted Proapoptotic Peptides Depleting Adipose Stromal Cells Inhibit Tumor Growth. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[283] R. Ladner,et al. Drugs derived from phage display , 2014, mAbs.
[284] D. Ribatti,et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[285] T. Minko,et al. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA , 2011, Journal of drug targeting.
[286] J. Zink,et al. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[287] J. Ho,et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. , 2010, ACS nano.
[288] Wadih Arap,et al. In vivo phage display and vascular heterogeneity: implications for targeted medicine. , 2002, Current opinion in chemical biology.
[289] D. Laván,et al. Synthetic Protocells Interact with Viral Nanomachinery and Inactivate Pathogenic Human Virus , 2011, PloS one.
[290] G. Watkins,et al. Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer , 2006, Annals of Surgical Oncology.
[291] G. Kroemer,et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. , 2011, Cancer research.
[292] Jeffrey I Zink,et al. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. , 2015, Small.
[293] Yunfeng Lu,et al. Aerosol-assisted self-assembly of mesostructured spherical nanoparticles , 1999, Nature.
[294] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[295] S. Groshen,et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. , 2007, Human pathology.
[296] H. Harashima,et al. A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[297] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[298] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[299] A. Plückthun,et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. , 2000, Journal of molecular biology.
[300] H. Gu,et al. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy. , 2013, Biomaterials.
[301] M. Ozawa,et al. Techniques to decipher molecular diversity by phage display. , 2007, Methods in molecular biology.
[302] Geoffrey J Clark,et al. Magnetic nanoparticle-supported lipid bilayers for drug delivery. , 2015, Langmuir : the ACS journal of surfaces and colloids.
[303] Pieter Wesseling,et al. Aminopeptidase A is a functional target in angiogenic blood vessels. , 2004, Cancer cell.
[304] A. D. de Kroon,et al. Ligation Strategies for Targeting Liposomal Nanocarriers , 2014, BioMed research international.
[305] Lev Dykman,et al. Analytical and Theranostic Applications of Gold Nanoparticles and Multifunctional Nanocomposites , 2013, Theranostics.
[306] D. Porteous,et al. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[307] Claus-Michael Lehr,et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. , 2009, Oligonucleotides.
[308] Timo Sorsa,et al. Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.
[309] W. Arap,et al. Teratogenicity induced by targeting a placental immunoglobulin transporter , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[310] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[311] G. Batist,et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[312] Min Zhang,et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.
[313] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[314] Zongxi Li,et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. , 2011, ACS nano.
[315] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[316] K. Gelmon,et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[317] Weixuan 'Vincent' Chen,et al. Thiol Reactive Probes and Chemosensors , 2012, Sensors.
[318] Jie Huang,et al. Polyethylenimine-functionalized graphene oxide as an efficient gene delivery vector , 2011 .
[319] Xinling Yang,et al. Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells. , 2015, International journal of clinical and experimental pathology.
[320] Chin-Tu Chen,et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. , 2010, Biomaterials.
[321] L. Marchetti,et al. Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells , 2015, Molecular therapy. Nucleic acids.
[322] I. Fidler,et al. Targeted Induction of Lung Endothelial Cell Apoptosis Causes Emphysema-like Changes in the Mouse , 2008, Journal of Biological Chemistry.
[323] R. Sidman,et al. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer , 2015, Proceedings of the National Academy of Sciences.
[324] Robert Gurny,et al. Current methods for attaching targeting ligands to liposomes and nanoparticles. , 2004, Journal of pharmaceutical sciences.
[325] Ying Liu,et al. Characterization of gold nanorods in vivo by integrated analytical techniques: their uptake, retention, and chemical forms , 2010, Analytical and bioanalytical chemistry.
[326] Gang Zheng,et al. Facile synthesis of Raman active phospholipid gold nanoparticles. , 2010, Bioconjugate chemistry.
[327] Joseph M. Fox,et al. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. , 2008, Journal of the American Chemical Society.
[328] J. Conde,et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. , 2012, ACS nano.
[329] P. Pavlík,et al. High-throughput screening of single-chain antibodies using multiplexed flow cytometry. , 2007, Journal of proteome research.
[330] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[331] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[332] R. Hodges,et al. Designing Heterodimeric Two-stranded α-Helical Coiled-coils , 2002, The Journal of Biological Chemistry.
[333] Carolyn R. Bertozzi,et al. Copper-free click chemistry for dynamic in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[334] Yaping Li,et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. , 2011, Small.
[335] Linlin Li,et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. , 2013, Biomaterials.
[336] Chad A. Mirkin,et al. Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma , 2013, Science Translational Medicine.
[337] Hendrik G. Stunnenberg,et al. Affinity purification of histidine-tagged proteins , 1993, Molecular Biology Reports.
[338] J. Marks,et al. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. , 2010, Journal of molecular biology.
[339] Kwangmeyung Kim,et al. Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. , 2012, Angewandte Chemie.
[340] H. Ali-Boucetta,et al. Pharmacology of carbon nanotubes: toxicokinetics, excretion and tissue accumulation. , 2013, Advanced drug delivery reviews.
[341] S. Sprang,et al. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP , 1993, Cell.
[342] J. Hainfeld,et al. Ni-NTA-gold clusters target His-tagged proteins. , 1999, Journal of structural biology.
[343] G. Storm,et al. Biosynthetically lipid‐modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes , 1996, FEBS letters.
[344] Patrick Couvreur,et al. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. , 2012, Chemical reviews.
[345] U. Nielsen,et al. A novel assay for monitoring internalization of nanocarrier coupled antibodies , 2006, BMC Immunology.
[346] Donald L Weaver,et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. , 2006, Cancer research.
[347] W. Arap,et al. A Ligand Peptide Motif Selected from a Cancer Patient Is a Receptor-Interacting Site within Human Interleukin-11 , 2008, PloS one.
[348] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[349] E. Vazquez,et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. , 2008, The Journal of clinical investigation.
[350] Taeghwan Hyeon,et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. , 2008, Angewandte Chemie.
[351] Yong Ren,et al. Recent advances in nanoparticle-mediated siRNA delivery. , 2014, Annual review of biomedical engineering.
[352] Brian G. Trewyn,et al. Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration , 2008 .
[353] S. Krishnan,et al. Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. , 2014, Cancer letters.